Cytel's Response: FDA Guidance On Conduct Of Clinical Trials During The COVID-19 Pandemic
Source: Cytel
The FDA recently issued a guidance on how the COVID-19 Pandemic may affect the conduct of clinical trials. following are some key messages from the guidance along with some interpretations and recommendations on topics including
- Completing Data Collection
- Handling Missing Information
- Protocol Modifications for Efficacy Assessments
- Amendments to Data Management and Statistical Analysis Plan
access the Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
This website uses cookies to ensure you get the best experience on our website. Learn more